Information  X 
Enter a valid email address

Uniphar PLC (UPR)

  Print      Mail a friend

Tuesday 19 November, 2019

Uniphar PLC


RNS Number : 8107T
Uniphar PLC
19 November 2019

Uniphar plc Acquisitions

Uniphar plc marks its entry into Nordic and Baltic markets with the acquisition of leading international medtech service provider EPS Group and also announces the acquisition of Irish Medtech service provider M3 Medical  

Dublin, London | 19 November 2019: Uniphar plc (the "Group") today announces its acquisition of Nordic-based medtech service provider, EPS Group and Irish-based medtech service provider M3 Medical Limited (M3 Medical).

The EPS Group comprises EPS Vascular AB and EP Endovascular AB, both registered in Sweden and EPS Vascular OY registered in Finland. M3 Medical is an Irish registered business. Both the EPS Group and M3 Medical deliver sales, marketing and distribution services to medical device manufacturers in the therapeutic areas of interventional cardiology and vascular medicine. The EPS Group delivers these services across Sweden, Denmark, Norway, Finland, Iceland and the Baltics, while M3 Medical's services extend exclusively to the Irish market.

This cluster of acquisitions represent another important development in the roll-out of Uniphar's pan-European growth strategy for its Commercial & Clinical division, which is focussed on acquiring local expertise and broadening its capacity to provide sales, marketing and distribution services for medical device manufacturers on a pan-European basis.


On a proforma basis for the full year ending 31 December 2019, these acquisitions in aggregate are expected to deliver revenue of an estimated €22m. Both the EPS Group and M3 Medical will be integrated into the Commercial & Clinical Medtech division of Uniphar. The total potential consideration payable to the vendors of the EPS Group and M3 Medical is €40m over four years, the deferred consideration to be linked to EBITDA performance over the four years.


Commenting on today's announcement

Ger Rabbette, CEO of Uniphar said:


"We are delighted to welcome our new colleagues from EPS and M3 to the Uniphar Group. These acquisitions are a key strategic step in Uniphar's plan to offer its pharmaco-medical clients a pan-European service by adding  new countries and new agencies to our roster. With this development, we add to our already considerable expertise in the area of interventional technologies in key therapeutic areas, and Uniphar advances its ambition to become a leading independent distributor of medical devices throughout Europe. We expect to invest in these platforms in the short term as part of growing our unique and compelling proposition to emerging and specialist medical device manufacturers seeking a commercial partnership across their European business."


Joakim Eriksson, CEO of EPS Vascular said:


"We are delighted to be joining the Uniphar Group. We have built a strong relationship with the Uniphar management team and know that we share common values around technical excellence and impeccable customer service. Uniphar's impressive scale in medical devices in Europe offers an opportunity for us to work with their existing manufacturer clients in the Nordics while continuing to develop the existing EPS manufacturer base. We are excited to be part of a Group with such strong ambitions in Europe and with the talent and expertise to make those ambitions a reality."



Killian O'Dowd, MD of M3 Medical:


"We at M3 Medical are excited to join the Uniphar Group. It gives us the opportunity to develop our existing relationships and to extend these across new geographies through Uniphar's growing European offering.  Uniphar's scale, digital solutions, regulatory expertise and impressive ambition in Europe will be a great platform for M3 Medical to grow and flourish in the years to come."


The acquisition of the EPS Group and M3 Medical were financed out of the proceeds of the placing completed alongside the listing of the Group's shares on 17 July 2019.



 --- ENDS ---


For further details contact:




Brian O'Shaughnessy

Director of Investor Relations and Corporate Development


+353 (0) 1 428 7777



[email protected]




(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)          


Fergal Meegan

Barry Murphy

Tom Tynan



+353 (0) 1 679 6363

RBC Capital Markets (Joint Broker)                                                                 

Darrell Uden

Jonathan Hardy

Jamil Miah



+44 (0) 20 7653 4000


(Public Relations Adviser to Uniphar)                                     


Iarla Mongey


+353 (0) 1 475 1444


+353 87 235 6461


About Uniphar plc


Headquartered in Dublin, Ireland, Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access, and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK, the Benelux, the US and now the Nordics following the acquisition of the EPS Group.


In Commercial & Clinical, the Group provides sales, marketing and distribution solutions to pharmaceutical and medical devices manufacturers on an outsourced basis.


In Product Access, the Group is growing two distinct service offerings: 1) sourcing and supplying unlicensed medicines to meet the needs of pharmacy customers (On-Demand Access); and 2) managing the release of speciality medicines for pharmaceutical manufacturers to specifically approved patient populations (Exclusive Access).


Supply Chain & Retail is an Irish only business for the Group, with Uniphar being an established market leader in Ireland with c.50% of the wholesale market servicing retail pharmacy, supported by a network of 258 owned and franchised pharmacies.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t